From memory to antifungal vaccine design

Trends in Immunology

Volumn 33, Issue 9, 2012, Pages 467-474

  Iannitti, Rossana G ^a   Carvalho, Agostinho ^a,b,c   Romani, Luigina ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF MINHO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; FUNGUS VACCINE;

ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ASPERGILLUS FUMIGATUS; BIOINFORMATICS; BLASTOMYCES DERMATITIDIS; CANDIDA ALBICANS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CRYPTOCOCCUS NEOFORMANS; DRUG DESIGN; DRUG EFFICACY; EFFECTOR CELL; HISTOPLASMA CAPSULATUM; HUMAN; IMMUNOGENETICS; IMMUNOLOGY; MALASSEZIA; MEMORY T LYMPHOCYTE; MYCOSIS; NONHUMAN; PNEUMOCYSTIS JIROVECI; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALS; ANTIGEN PRESENTATION; DRUG DESIGN; FUNGAL VACCINES; HOST SPECIFICITY; HUMANS; IMMUNOLOGIC MEMORY;

EID: 84865305503     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2012.04.008     Document Type: Review

References (73)

1. Datta K., Pirofski L.A. Towards a vaccine for Cryptococcus neoformans: principles and caveats. FEMS Yeast Res. 2006, 6:525-536.
2. Fidel P.L., Cutler J.E. Prospects for development of a vaccine to prevent and control vaginal candidiasis. Curr. Infect. Dis. Rep. 2011, 13:102-107.
3. Cassone A. Fungal vaccines: real progress from real challenges. Lancet Infect. Dis. 2008, 8:114-124.
4. Edwards J.E. Fungal cell wall vaccines: an update. J. Med. Microbiol. 2012, 61:895-903.
5. Ito J.I. T cell immunity and vaccines against invasive fungal diseases. Immunol. Invest. 2011, 40:825-838.
6. Stevens D.A., et al. Developing a vaccine against aspergillosis. Med. Mycol. 2011, 49(Suppl. 1):S170-S176.
7. Cutler J.E., et al. Advances in combating fungal diseases: vaccines on the threshold. Nat. Rev. Microbiol. 2007, 5:13-28.
8. Liu M., et al. Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection. Vaccine 2011, 29:1745-1753.
9. Cassone A., Rappuoli R. Universal vaccines: shifting to one for many. mBio 2010, 1. e00042-00010.
10. Romani L. Immunity to fungal infections. Nat. Rev. Immunol. 2011, 11:275-288.
11. Casadevall A., Pirofski L.A. The damage-response framework of microbial pathogenesis. Nat. Rev. Microbiol. 2003, 1:17-24.
12. Spellberg B. Vaccines for invasive fungal infections. F1000 Med. Rep. 2011, 3:13.
13. Littman D.R., Pamer E.G. Role of the commensal microbiota in normal and pathogenic host immune responses. Cell Host Microbe 2011, 10:311-323.
14. Rizzetto L., Cavalieri D. Friend or foe: using systems biology to elucidate interactions between fungi and their hosts. Trends Microbiol. 2011, 19:509-515.
15. Bonifazi P., et al. Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans. Mucosal Immunol. 2009, 2:362-374.
16. Cavassani K.A., et al. Systemic and local characterization of regulatory T cells in a chronic fungal infection in humans. J. Immunol. 2006, 177:5811-5818.
17. Deepe G.S., Gibbons R.S. TNF-alpha antagonism generates a population of antigen-specific CD4+CD25+ T cells that inhibit protective immunity in murine histoplasmosis. J. Immunol. 2008, 180:1088-1097.
18. Loures F.V., et al. TLR2 is a negative regulator of Th17 cells and tissue pathology in a pulmonary model of fungal infection. J. Immunol. 2009, 183:1279-1290.
19. Bozza S., et al. Immune sensing of Aspergillus fumigatus proteins, glycolipids, and polysaccharides and the impact on Th immunity and vaccination. J. Immunol. 2009, 183:2407-2414.
20. Romani L., Puccetti P. Protective tolerance to fungi: the role of IL-10 and tryptophan catabolism. Trends Microbiol. 2006, 14:183-189.
21. Pulendran B., et al. Systems vaccinology. Immunity 2010, 33:516-529.
22. Wuthrich M., et al. Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 cells in mice. J. Clin. Invest. 2011, 121:554-568.
23. De Luca A., et al. CD4 T cell vaccination overcomes defective cross-presentation of fungal antigens in murine Chronic Granulomatous Disease. J. Clin. Invest. 2012, 122:1816-1831.
24. Carvalho A., et al. TLR3 essentially promotes protective class I-restricted memory CD8+ T-cell responses to Aspergillus fumigatus in hematopoietic transplanted patients. Blood 2012, 119:967-977.
25. Levitz, S.M. and Golenbock, D.T. (2012) Beyond empiricism: informing vaccine development through innate immunity research. Cell 148, 1284-92.
26. Pulendran B., Ahmed R. Immunological mechanisms of vaccination. Nat. Immunol. 2011, 12:509-517.
27. Huang H., et al. Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded beta-glucan particles. mBio 2010, 1:e00164-e00210.
28. Torosantucci A., et al. A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 2005, 202:597-606.
29. Rachini A., et al. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect. Immun. 2007, 75:5085-5094.
30. Xin H., et al. Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:13526-13531.
31. Bromuro C., et al. Beta-glucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine 2010, 28:2615-2623.
32. Sallusto F., et al. From vaccines to memory and back. Immunity 2010, 33:451-463.
33. Nanjappa S.G., et al. Protective antifungal memory CD8+ T cells are maintained in the absence of CD4+ T cell help and cognate antigen in mice. J. Clin. Invest. 2012, 122:987-999.
34. Medeiros A.I., et al. Leukotrienes are potent adjuvant during fungal infection: effects on memory T cells. J. Immunol. 2008, 181:8544-8551.
35. Wuthrich M., et al. Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts. J. Exp. Med. 2003, 197:1405-1416.
36. Butler N.S., et al. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat. Immunol. 2012, 13:188-195.
37. Pearce E.L., et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009, 460:103-107.
38. van der Windt G.J., et al. Mitochondrial respiratory capacity is a critical regulator of CD8(+) T cell memory development. Immunity 2012, 36:68-78.
39. Cohen N.R., et al. Innate recognition of cell wall beta-glucans drives invariant natural killer T cell responses against fungi. Cell Host Microbe 2011, 10:437-450.
40. Spellberg B., et al. Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. J. Infect. Dis. 2008, 197:967-971.
41. Casadevall A., Pirofski L.A. A new synthesis for antibody-mediated immunity. Nat. Immunol. 2012, 13:21-28.
42. Magliani W., et al. Protective antifungal yeast killer toxin-like antibodies. Curr. Mol. Med. 2005, 5:443-452.
43. Diaz-Arevalo D., et al. CD4+ T cells mediate the protective effect of the recombinant Asp f3-based anti-aspergillosis vaccine. Infect. Immun. 2011, 79:2257-2266.
44. Cenci E., et al. T cell vaccination in mice with invasive pulmonary aspergillosis. J. Immunol. 2000, 165:381-388.
45. Ito J.I., et al. Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis. Infect. Immun. 2006, 74:5075-5084.
46. Stuehler C., et al. Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood 2011, 117:5881-5891.
47. Lam J.S., et al. A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity. J. Immunol. 2005, 175:7496-7503.
48. de Bastos Ascenco Soares R., et al. Vaccination with heat shock protein 60 induces a protective immune response against experimental Paracoccidioides brasiliensis pulmonary infection. Infect. Immun. 2008, 76:4214-4221.
49. Shubitz L.F., et al. Improved protection of mice against lethal respiratory infection with Coccidioides posadasii using two recombinant antigens expressed as a single protein. Vaccine 2006, 24:5904-5911.
50. Tarcha E.J., et al. A recombinant aspartyl protease of Coccidioides posadasii induces protection against pulmonary coccidioidomycosis in mice. Infect. Immun. 2006, 74:516-527.
51. De Luca A., et al. IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol. 2010, 3:361-373.
52. Spellberg B.J., et al. Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J. Infect. Dis. 2006, 194:256-260.
53. Lin L., et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathogens 2009, 5:e1000703.
54. Plotkin S.A. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 2008, 47:401-409.
55. Romani L., et al. Fungi, dendritic cells and receptors: a host perspective of fungal virulence. Trends Microbiol. 2002, 10:508-514.
56. Wuthrich M., et al. Adaptive immunity to fungi. Annu. Rev. Immunol. 2011, 30:115-148.
57. Bozza S., et al. Dendritic cell-based vaccination against opportunistic fungi. Vaccine 2004, 22:857-864.
58. Zheng M., et al. CD4+ T cell-independent vaccination against Pneumocystis carinii in mice. J. Clin. Invest. 2001, 108:1469-1474.
59. Hsieh S.H., et al. Immunization with apoptotic phagocytes containing Histoplasma capsulatum activates functional CD8(+) T cells to protect against histoplasmosis. Infect. Immun. 2011, 79:4493-4502.
60. Ersland K., et al. Dynamic interplay among monocyte-derived, dermal, and resident lymph node dendritic cells during the generation of vaccine immunity to fungi. Cell Host Microbe 2010, 7:474-487.
61. Awasthi S. Dendritic cell-based vaccine against coccidioides infection. Ann. N.Y. Acad. Sci. 2007, 1111:269-274.
62. Bozza S., et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 2003, 102:3807-3814.
63. Magalhaes A., et al. Prophylactic and therapeutic vaccination using dendritic cells primed with peptide 10 derived from the 43 kDa glycoprotein of Paracoccidioides brasiliensis. Clin. Vaccine Immunol. 2011, 10.1128/CVI.05414-11.
64. Coffman R.L., et al. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503.
65. Burgdorf S., Kurts C. Endocytosis mechanisms and the cell biology of antigen presentation. Curr. Opin. Immunol. 2008, 20:89-95.
66. Luong M., et al. Effects of fungal N- and O-linked mannosylation on the immunogenicity of model vaccines. Vaccine 2007, 25:4340-4344.
67. Wozniak K.L., Levitz S.M. Cryptococcus neoformans enters the endolysosomal pathway of dendritic cells and is killed by lysosomal components. Infect. Immun. 2008, 76:4764-4771.
68. Saveanu L., et al. IRAP identifies an endosomal compartment required for MHC class I cross-presentation. Science 2009, 325:213-217.
69. Savina A., et al. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell 2006, 126:205-218.
70. Crotzer V.L., Blum J.S. Autophagy and adaptive immunity. Immunology 2010, 131:9-17.
71. Poland G.A., Oberg A.L. Vaccinomics and bioinformatics: accelerants for the next golden age of vaccinology. Vaccine 2010, 28:3509-3510.
72. Cunha C., et al. Immunogenetic profiling to predict risk of invasive fungal diseases: where are we now?. Immunol. Invest. 2011, 40:723-734.
73. Santamaria R., et al. Systems biology of infectious diseases: a focus on fungal infections. Immunobiology 2011, 216:1212-1227.